Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial

Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial Publisher

Daneshimaskooni M¹ ; Keshavarz SA² ; Qorbani M³ ; Mansouri S⁴ ; Alavian SM⁵ ; Badrifariman M¹ ; Jazayeritehrani SA² ; Sotoudeh G¹

Show Affiliations

1. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, No.44, Hojjatdoust Alley, Naderi Ave, Keshavarz Blvd, Tehran, 1416643931, Iran
2. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
3. Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
4. Gastroenterohepatology Department, National Iranian Oil Company (NIOC), Central Hospital, Tehran, Iran
5. Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, Iran

Source: Nutrition and Metabolism Published:2018

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of metabolic syndrome. Despite the beneficial health effects of cardamom on dyslipidemia, hepatomegaly, and fasting hyperglycemia, no previous human study has been conducted on the efficacy of cardamom in NAFLD. The aim of this study was to assess the effects of green cardamom (GC) on serum Sirtuin-1 (Sirt1), inflammatory factors, and liver enzymes in overweight or obese NAFLD patients. Methods: The recruitment of subjects was conducted at the polyclinic of the central hospital of National Iranian Oil Company (NIOC), Tehran. Eighty-seven patients who participated were divided randomly into two groups according to the ultrasonography and eligibility criteria as cardamom (n = 43) or placebo (n = 44). The intervention involves taking two 500 mg capsules three times per day with meals for 3 months. General characteristics, dietary intake and physical activity status, weight and height were determined. In addition, serum Sirt1, tumor necrosis factor-alpha (TNF-α), high sensitive c-reactive protein (hs-CRP), interleukin-6 (IL-6), alanine transaminase (ALT), and aspartate transaminase (AST) were measured. The degree of fatty liver was determined at beginning and end of the study. Results: In comparison with placebo, GC significantly increased Sirt1 and decreased hs-CRP, TNF-α, IL-6, ALT, and the degree of fatty liver (P < 0.05). The differences in weight, BMI, and AST were not significant (P > 0.05). Conclusion: GC supplementation could improve some biomarkers related to fatty liver including inflammation, ALT, and Sirt1 in overweight/obese NAFLD patients. Further trials on cardamom's potential are suggested. Trial registration: Iranian Registry of Clinical Trials, IRCT2015121317254N4. Registered 27/12/2015. © 2018 The Author(s).

Related Docs

View other Related Docs

1. Green Cardamom Supplementation Improves Serum Irisin, Glucose Indices, and Lipid Profiles in Overweight or Obese Non-Alcoholic Fatty Liver Disease Patients: A Double-Blind Randomized Placebo-Controlled Clinical Trial, BMC Complementary and Alternative Medicine (2019)

2. The Effects of Green Cardamom on Blood Glucose Indices, Lipids, Inflammatory Factors, Paraxonase-1, Sirtuin-1, and Irisin in Patients With Nonalcoholic Fatty Liver Disease and Obesity: Study Protocol for a Randomized Controlled Trial, Trials (2017)

3. Efficacy of Nanocurcumin Supplementation on Insulin Resistance, Lipids, Inflammatory Factors and Nesfatin Among Obese Patients With Non-Alcoholic Fatty Liver Disease (Nafld): A Trial Protocol, BMJ Open (2017)

4. The Effects of Green Cardamom Supplementation on Blood Glucose, Lipids Profile, Oxidative Stress, Sirtuin-1 and Irisin in Type 2 Diabetic Patients: A Study Protocol for a Randomized Placebo-Controlled Clinical Trial, BMC Complementary and Alternative Medicine (2018)

5. The Effects of Elettaria Cardamom Supplementation on Inflammatory Markers and Vascular Function in Patients With Type 2 Diabetes Mellitus: A Mechanism -Based Randomized Clinical Trial, Journal of Herbal Medicine (2021)

6. Cardamom Supplementation Improves Inflammatory and Oxidative Stress Biomarkers in Hyperlipidemic, Overweight, and Obese Pre-Diabetic Women: A Randomized Double-Blind Clinical Trial, Journal of the Science of Food and Agriculture (2017)

7. Nano-Curcumin Improves Glucose Indices, Lipids, Inflammation, and Nesfatin in Overweight and Obese Patients With Non-Alcoholic Fatty Liver Disease (Nafld): A Double-Blind Randomized Placebo-Controlled Clinical Trial, Nutrition and Metabolism (2019)

8. The Effects of Green Cardamom Supplementation on Blood Pressure and Endothelium Function in Type 2 Diabetic Patients a Study Protocol for a Randomized Controlled Clinical Trial, Medicine (United States) (2020)

Experts (# of related papers)

View all Related Experts

Ensieh Nasli Esfahani (4)

Mohammad Javad Hosseinzadeh Attar (4)

Style	Citing Format
MLA	Daneshimaskooni M, et al.. "Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial." Nutrition and Metabolism, vol. 15, no. 1, 2018, pp. -.
APA	Daneshimaskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badrifariman M, Jazayeritehrani SA, Sotoudeh G (2018). Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Nutrition and Metabolism, 15(1), -.
Chicago	Daneshimaskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badrifariman M, Jazayeritehrani SA, Sotoudeh G. "Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial." Nutrition and Metabolism 15, no. 1 (2018): -.
Harvard	Daneshimaskooni M et al. (2018) 'Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial', Nutrition and Metabolism, 15(1), pp. -.
Vancouver	Daneshimaskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badrifariman M, et al.. Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Nutrition and Metabolism. 2018;15(1):-.
BibTex	@article{ author = {Daneshimaskooni M and Keshavarz SA and Qorbani M and Mansouri S and Alavian SM and Badrifariman M and Jazayeritehrani SA and Sotoudeh G}, title = {Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial}, journal = {Nutrition and Metabolism}, volume = {15}, number = {1}, pages = {-}, year = {2018} }
RIS	TY - JOUR AU - Daneshimaskooni M AU - Keshavarz SA AU - Qorbani M AU - Mansouri S AU - Alavian SM AU - Badrifariman M AU - Jazayeritehrani SA AU - Sotoudeh G TI - Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial JO - Nutrition and Metabolism VL - 15 IS - 1 SP - EP - PY - 2018 ER -

Style

Citing Format

MLA

Daneshimaskooni M, et al.. "Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial." Nutrition and Metabolism, vol. 15, no. 1, 2018, pp. -.

APA

Daneshimaskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badrifariman M, Jazayeritehrani SA, Sotoudeh G (2018). Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Nutrition and Metabolism, 15(1), -.

Chicago

Daneshimaskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badrifariman M, Jazayeritehrani SA, Sotoudeh G. "Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial." Nutrition and Metabolism 15, no. 1 (2018): -.

Harvard

Daneshimaskooni M et al. (2018) 'Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial', Nutrition and Metabolism, 15(1), pp. -.

Vancouver

Daneshimaskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badrifariman M, et al.. Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial. Nutrition and Metabolism. 2018;15(1):-.

BibTex

@article{ author = {Daneshimaskooni M and Keshavarz SA and Qorbani M and Mansouri S and Alavian SM and Badrifariman M and Jazayeritehrani SA and Sotoudeh G}, title = {Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial}, journal = {Nutrition and Metabolism}, volume = {15}, number = {1}, pages = {-}, year = {2018} }

RIS

TY - JOUR
AU - Daneshimaskooni M
AU - Keshavarz SA
AU - Qorbani M
AU - Mansouri S
AU - Alavian SM
AU - Badrifariman M
AU - Jazayeritehrani SA
AU - Sotoudeh G
TI - Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial
JO - Nutrition and Metabolism
VL - 15
IS - 1
SP -
EP -
PY - 2018
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract